JANUX THERAPEUTICS Reports Q2 FY2023 Earnings with 55.3% Decrease in Total Revenue

August 12, 2023

🌥️Earnings Overview

JANUX THERAPEUTICS ($NASDAQ:JANX) reported total revenue of USD 1.1 million for the second quarter of FY2023, a decrease of 55.3% compared to the same period last year, on June 30 2023. Net income for the quarter was USD -17.5 million, a slight increase from the -16.9 million reported in the same period the previous year.


GoodWhale conducted an analysis of JANUX THERAPEUTICS‘s wellbeing, and the results were displayed on a Star Chart. An analysis of the company revealed that they are strong in assets and growth, but weak in dividend and profitability. Based on this, we classified JANUX THERAPEUTICS as a ‘cheetah’, a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. This type of company may be attractive to investors who seek a higher risk/reward ratio, as well as those who look for growth opportunities within the biotech sector. Investors may also be interested in JANUX THERAPEUTICS’ low debt-to-equity ratio, which suggests that they can carry out more projects without taking on additional debt. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Janux Therapeutics. More…

    Total Revenues Net Income Net Margin
    7.76 -67.73 -872.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Janux Therapeutics. More…

    Operations Investing Financing
    -54.29 27.29 2.3
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Janux Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    341.5 42.03 6.51
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Janux Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -769.5% -15.8% -14.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    Janux’s lead product candidate, JTX-2011, is a first-in-class immunotherapy that targets the CD47 protein. Janux is also developing JTX-2028, a second generation immunotherapy that targets the CD47 protein. Janux’s competitors include IO Biotech Inc, Immune Therapeutics Inc, and Larimar Therapeutics Inc.

    – IO Biotech Inc ($NASDAQ:IOBT)

    AcelRx Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the research, development, and commercialization of therapies for the treatment of acute pain. Its product candidates include DSUVIA/SUVIA, which is designed to provide rapid onset and durable analgesia; and Zalviso, a sublingual formulation of sufentanil delivered through a pre-programmed, patient-controlled analgesia delivery device. The company was founded by Pamela P. Palmer, M.D., Ph.D. and Richard King on March 15, 2005 and is headquartered in Redwood City, CA.

    – Immune Therapeutics Inc ($OTCPK:IMUN)

    Immune Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapies for the treatment of cancer, autoimmune and infectious diseases. The company’s lead product candidate is Melacine, which is in Phase III clinical trials for the treatment of metastatic melanoma. The company’s other product candidates include MDX-1308, MDX-1401 and MDX-1501.

    – Larimar Therapeutics Inc ($NASDAQ:LRMR)

    Larimar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. The company’s lead product candidate, LT-300, is a T-cell therapy that is being studied in a Phase 1/2 clinical trial in patients with relapsed or refractory solid tumors. Larimar has a market cap of $132.84 million and an ROE of -73.95%.


    JANUX THERAPEUTICS reported total revenue of USD 1.1 million for the second quarter of FY2023, a decrease of 55.3% year-on-year. Net income was reported at USD -17.5 million, a slight increase from the previous year. Investors should take note of the sharp decline in revenue as well as the company’s continued losses.

    They should assess whether the business model and financials are sound enough for a potential investment in the company. Furthermore, investors should pay attention to how JANUX THERAPEUTICS plans to turn around their fortunes and deliver returns on investment.

    Recent Posts

    Leave a Comment